Lung cancer is still the leading cause of cancer-related death, claiming 1.8 million lives each year. While immunotherapy has helped, nearly half of patients carry genomic mutations that limit its effectiveness – driving a surge in precision medicine solutions. These therapies, guided by genomic profiling, are not only improving survival rates but also transforming the treatment landscape. Our latest deep dive report examines this transformation in detail – highlighting the data, developments and drugmakers driving a projected $22 billion global market by 2030.

Download this report and discover:

• Market Outlook: A breakdown of the precision therapy market for NSCLC, including forecasts by mutation type (EGFR, KRAS, ALK, HER2, ROS1 and more).
• Pipeline Progress: An overview of more than 20 approved therapies and key programs in development, including next-gen KRAS and EGFR inhibitors.
• Commercial Impact: Insight into which pharma companies stand to gain most –AstraZeneca, Roche, BMS, Pfizer, Lilly – and why.
• Growth Catalysts: Upcoming clinical trial readouts, approval timelines and combination therapy strategies set to shape the competitive landscape.
• Challenges to Watch: Drug resistance trends, diagnostic testing limitations and pricing pressures – especially in the China market.
• Strategic Implications: How stakeholders are adapting their portfolios, R&D strategies and partnerships in response to evolving molecular targets.

This report will arm you with the insights you need to navigate one of the most dynamic therapeutic areas today.